In re Application of: Joel E. Bernstein

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner: Art Unit: 1614

Serial Number: 10/813,760

Filed: March 31, 2004

For:

Compositions with Reduced

Hepatotoxicity

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Applicant is submitting this Supplemental Information Disclosure Statement to submit patents of which he is aware, which he believes may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

Specifically, on July 15, 2005, Applicant received an International Search Report relative to International application no. PCT/US2005/09795 corresponding to the above application. In the Search Report, the art referenced herein on the attached PTO form 1449 was considered to be relevant. For convenience, a copy of the reference is enclosed herewith.

I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

It is respectfully submitted that the present application is patentable over these references, whether taken singly or in combination. Applicant is submitting these references for

consideration by the Examiner and for purposes of entering these citations in the official file in order to comply with his duty of candor.

While the information included in this Information Disclosure Statement may be "material" pursuant to 37 C.F.R. 1.56, it is not intended to constitute an admission that any patent or other art referred to herein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 C.F.R. 1.97(g) and (h), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. 1.56 exists.

Although applicant believes that no fee is required relative to this submission, the Examiner is hereby authorized to charge any fee which may be required for the proper filing of this Information Disclosure Statement to Deposit Account No. 10-1202.

Respectfully submitted,

Marc S. Blackman Reg. No. 43,501

JONES DAY

77 West Wacker

Chicago, Illinois 60601-1692

(312) 782-3939

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class Mail in an envelope addressed to:

Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on August 19,

2005.

Patricia A. Merrill

FORM PTO-144 (Rev. 2-32)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary									ATTY DOCKET NO.  812540605046  APPLICANT: Joel  FILING DATE:  March 31, 2004		APPLICATION U.S. SERIAL NO.: 10/813,760  E. Bernstein  GROUP: 1614		
Ta III							U.	S. PA	TENT DOC	CUMENTS			-	
EXAMINER . INITIAL			DOCUMENT NUMBER						DATE	NAME	CLASS	SUB- CLASS	l I	DATE F PRIATE
		ļ	ļ	<u> </u>			<u> </u>	ļ						
		-	-	-	<u> </u>	<u> </u>	<u> </u>	-			<del></del>			<del></del>
		<del> </del>	<del> </del>	<del> </del>		├─	├─	<del> </del>			<del>                                     </del>			
<u> </u>		<del> </del>	<del> </del>	-	$\vdash$		╁	-			<del> </del>			<del></del>
		+-		1		<del> </del>	<del>                                     </del>				+			•
			<b>!</b>	<b> </b>	1		$\vdash$				†		ļ	
					<u> </u>	†	l	<del>                                     </del>			<del> </del>			
				1	1	1	1		<u> </u>				·	· · · · · · · · · · · · · · · · · · ·
									<u> </u>					
						F	ORE	IGN	PATENT D	OCUMENTS				
	DOCUMENT NUMBER DATE								DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
	<u></u>											YES	NO	
									<u></u>					
-				THE	R DO	CUM	ENTS	(Incl	uding Author,	Title, Date, Pertinent Page	s, Etc.)			
		Kroger, H. et al., "Protection from acetaminophen-induced liver damage by the synergistic action of low doses of the poly (ADP-ribose) polymerase-inhibitor nicotinamide and the antioxidant N-acetylcysteine or the amino acid L-methionine, General Pharmacology, Vol. 28, No. 2, pp. 257-263 (1997).												
l														
Ĺ					,									
EXAMINER							_		DATE CONS					
										in conformance with N				h

(Form PTO-1449 [6-4])